1. Home
  2. CTMX vs EVV Comparison

CTMX vs EVV Comparison

Compare CTMX & EVV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CytomX Therapeutics Inc.

CTMX

CytomX Therapeutics Inc.

HOLD

Current Price

$3.54

Market Cap

977.1M

Sector

Health Care

ML Signal

HOLD

Logo Eaton Vance Limited Duration Income Fund of Beneficial Interest

EVV

Eaton Vance Limited Duration Income Fund of Beneficial Interest

HOLD

Current Price

$9.37

Market Cap

1.1B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
CTMX
EVV
Founded
2008
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance/Investors Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
977.1M
1.1B
IPO Year
2015
2003

Fundamental Metrics

Financial Performance
Metric
CTMX
EVV
Price
$3.54
$9.37
Analyst Decision
Strong Buy
Analyst Count
10
0
Target Price
$12.10
N/A
AVG Volume (30 Days)
2.8M
363.8K
Earning Date
05-08-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$76,201,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$7.61
N/A
P/E Ratio
$22.58
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.72
$8.97
52 Week High
$8.21
$10.41

Technical Indicators

Market Signals
Indicator
CTMX
EVV
Relative Strength Index (RSI) 34.50 50.70
Support Level $3.40 $8.97
Resistance Level $3.91 $9.59
Average True Range (ATR) 0.17 0.10
MACD 0.01 0.02
Stochastic Oscillator 24.14 79.41

Price Performance

Historical Comparison
CTMX
EVV

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

About EVV Eaton Vance Limited Duration Income Fund of Beneficial Interest

Eaton Vance Ltd Duration Income Fund is a diversified closed-end management investment company. The company's investment objective is to provide a high level of current income. The Fund also seeks capital appreciation. The Fund invests predominantly in Senior Floating-Rate Loans, Debt Obligations, Equity Securities, Derivatives as well as Foreign Securities and Currencies. The Fund invests in various industries, including aerospace and defense, automotive, building and development, healthcare, and leisure, among others.

Share on Social Networks: